Marta Milà‐Alomà

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

Andréa Lessa Benedet, Marta Milà‐Alomà, Agathe Vrillon et al. · JAMA Neurology · 2021 · 631 citations · Full text

Medicine, Neurology, Neuroscience +17

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Marc Suárez‐Calvet, Thomas K. Karikari, Juan Lantero‐Rodriguez et al. · EMBO Molecular Medicine · 2020 · 414 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Marta Milà‐Alomà, Nicholas J. Ashton, Mahnaz Shekari et al. · Nature Medicine · 2022 · 349 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's <i>continuum</i>

Marta Milà‐Alomà, Gemma Salvadó, Juan Domingo Gispert et al. · Alzheimer s & Dementia · 2020 · 263 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays

Nicholas J. Ashton, Albert Puig‐Pijoan, Marta Milà‐Alomà et al. · Alzheimer s & Dementia · 2022 · 224 citations · Full text

Medicine, Neurology, Neuroscience +17